Reduced prevalence of serum antibodies against adeno-associated virus type 2 in patients with adult T-cell leukaemia lymphoma
Seroepidemiological studies have shown previously that cancer patients are less likely to have antibodies against the tumour suppressive adeno‐associated virus (AAV) than control groups. To examine the influence of AAV infection on the development of adult T‐cell leukaemia lymphoma (ATLL), an endemi...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 2001-09, Vol.65 (1), p.185-189 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 189 |
|---|---|
| container_issue | 1 |
| container_start_page | 185 |
| container_title | Journal of medical virology |
| container_volume | 65 |
| creator | Walz, Christian M. Nakamura, Minoru Fukunaga, Toshihiko Jasiewicz, Yvonne Edler, Lutz Schlehofer, Jörg R. Tanaka, Yuetsu |
| description | Seroepidemiological studies have shown previously that cancer patients are less likely to have antibodies against the tumour suppressive adeno‐associated virus (AAV) than control groups. To examine the influence of AAV infection on the development of adult T‐cell leukaemia lymphoma (ATLL), an endemic disease in Southern Japan that is caused by infection with the human T‐cell leukaemia virus type 1 (HTLV‐I), the prevalence of serum antibodies to AAV type 2 (AAV‐2) was tested in healthy HTLV‐I carriers (n = 39) and patients with ATLL (n = 31). The results showed a significant difference in AAV‐2 seropositivity between the two groups: Only 29% of the ATLL patients had IgG antibodies against AAV‐2, whereas 84.6% of the healthy HTLV‐I carriers were seropositive. Analysis of total serum IgG and antibodies against the Epstein‐Barr virus (EBV) EBNA1 antigen showed that the lack of AAV antibodies in patients was not due to an ATLL‐associated immune deficiency. The lower level of AAV‐2 seropositivity in ATLL‐patients may indicate that AAV‐2 antibody‐positive HTLV‐I carriers might be less likely to develop ATLL or that loss of AAV‐2 antibodies may parallel the development of disease. J. Med. Virol. 65:185–189, 2001. © 2001 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/jmv.2019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71091292</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17902885</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4169-8ac2b111744cf66b2c6692889e50b6a27be95eed439afdc801e1f31bf538428e3</originalsourceid><addsrcrecordid>eNqF0U1v1DAQBmALgei2IPELkC9UvaT1OIkTH1FFW1BbECofN2viTKjbfGE7W_bAfyerjegJcfLl8TujeRl7BeIYhJAnd936WArQT9gKhFaJFgU8ZSsBmUqUgnyP7YdwJ4QotZTP2R5ALvJMyRX7_ZnqyVLNR09rbKm3xIeGB_JTx7GPrhpqR4HjD3R9iBxr6ocEQxiswzj_Wzs_BR43I3HJXc9HjI76GPiDi7czn9rIbxJLbctbmu6ROoe83XTj7dDhC_aswTbQy-U9YF_O3t2cXiSXH8_fn769TGwGSiclWlkBQJFltlGqklYpLctSUy4qhbKoSOdEdZZqbGpbCiBoUqiaPC0zWVJ6wA53uaMffk4Uoulc2O6EPQ1TMMV8NZBa_hdCocU8OJ_h0Q5aP4TgqTGjdx36jQFhtp2YuROz7WSmr5fMqeqofoRLCTN4swAMFtvGY29deHTzDbJSbIOSnXtwLW3-OdB8uPq6DF68C5F-_fXo740q0iI3367PjSqlzD9dnZnv6R8V8bKf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17902885</pqid></control><display><type>article</type><title>Reduced prevalence of serum antibodies against adeno-associated virus type 2 in patients with adult T-cell leukaemia lymphoma</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Walz, Christian M. ; Nakamura, Minoru ; Fukunaga, Toshihiko ; Jasiewicz, Yvonne ; Edler, Lutz ; Schlehofer, Jörg R. ; Tanaka, Yuetsu</creator><creatorcontrib>Walz, Christian M. ; Nakamura, Minoru ; Fukunaga, Toshihiko ; Jasiewicz, Yvonne ; Edler, Lutz ; Schlehofer, Jörg R. ; Tanaka, Yuetsu</creatorcontrib><description>Seroepidemiological studies have shown previously that cancer patients are less likely to have antibodies against the tumour suppressive adeno‐associated virus (AAV) than control groups. To examine the influence of AAV infection on the development of adult T‐cell leukaemia lymphoma (ATLL), an endemic disease in Southern Japan that is caused by infection with the human T‐cell leukaemia virus type 1 (HTLV‐I), the prevalence of serum antibodies to AAV type 2 (AAV‐2) was tested in healthy HTLV‐I carriers (n = 39) and patients with ATLL (n = 31). The results showed a significant difference in AAV‐2 seropositivity between the two groups: Only 29% of the ATLL patients had IgG antibodies against AAV‐2, whereas 84.6% of the healthy HTLV‐I carriers were seropositive. Analysis of total serum IgG and antibodies against the Epstein‐Barr virus (EBV) EBNA1 antigen showed that the lack of AAV antibodies in patients was not due to an ATLL‐associated immune deficiency. The lower level of AAV‐2 seropositivity in ATLL‐patients may indicate that AAV‐2 antibody‐positive HTLV‐I carriers might be less likely to develop ATLL or that loss of AAV‐2 antibodies may parallel the development of disease. J. Med. Virol. 65:185–189, 2001. © 2001 Wiley‐Liss, Inc.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.2019</identifier><identifier>PMID: 11505462</identifier><identifier>CODEN: JMVIDB</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>AAV ; Adeno-associated virus 2 ; Adeno-associated virus type 2 ; Antibodies, Viral - blood ; ATLL ; Biological and medical sciences ; Carrier State ; Dependovirus - immunology ; EBNA1 antigen ; ELISA ; Epstein-Barr virus ; Female ; Fundamental and applied biological sciences. Psychology ; HTLV-I ; HTLV‐I, ELISA ; Human T-lymphotropic virus 1 ; Human T-lymphotropic virus 1 - immunology ; Humans ; Immunoglobulin G - blood ; Leukemia-Lymphoma, Adult T-Cell - immunology ; Leukemia-Lymphoma, Adult T-Cell - virology ; Male ; Microbiology ; Parvoviridae Infections - epidemiology ; Parvoviridae Infections - immunology ; Parvoviridae Infections - virology ; Prevalence ; Seroepidemiologic Studies ; seroepidemiology ; tumour suppression</subject><ispartof>Journal of medical virology, 2001-09, Vol.65 (1), p.185-189</ispartof><rights>Copyright © 2001 Wiley‐Liss, Inc.</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2001 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4169-8ac2b111744cf66b2c6692889e50b6a27be95eed439afdc801e1f31bf538428e3</citedby><cites>FETCH-LOGICAL-c4169-8ac2b111744cf66b2c6692889e50b6a27be95eed439afdc801e1f31bf538428e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.2019$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.2019$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14164809$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11505462$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walz, Christian M.</creatorcontrib><creatorcontrib>Nakamura, Minoru</creatorcontrib><creatorcontrib>Fukunaga, Toshihiko</creatorcontrib><creatorcontrib>Jasiewicz, Yvonne</creatorcontrib><creatorcontrib>Edler, Lutz</creatorcontrib><creatorcontrib>Schlehofer, Jörg R.</creatorcontrib><creatorcontrib>Tanaka, Yuetsu</creatorcontrib><title>Reduced prevalence of serum antibodies against adeno-associated virus type 2 in patients with adult T-cell leukaemia lymphoma</title><title>Journal of medical virology</title><addtitle>J. Med. Virol</addtitle><description>Seroepidemiological studies have shown previously that cancer patients are less likely to have antibodies against the tumour suppressive adeno‐associated virus (AAV) than control groups. To examine the influence of AAV infection on the development of adult T‐cell leukaemia lymphoma (ATLL), an endemic disease in Southern Japan that is caused by infection with the human T‐cell leukaemia virus type 1 (HTLV‐I), the prevalence of serum antibodies to AAV type 2 (AAV‐2) was tested in healthy HTLV‐I carriers (n = 39) and patients with ATLL (n = 31). The results showed a significant difference in AAV‐2 seropositivity between the two groups: Only 29% of the ATLL patients had IgG antibodies against AAV‐2, whereas 84.6% of the healthy HTLV‐I carriers were seropositive. Analysis of total serum IgG and antibodies against the Epstein‐Barr virus (EBV) EBNA1 antigen showed that the lack of AAV antibodies in patients was not due to an ATLL‐associated immune deficiency. The lower level of AAV‐2 seropositivity in ATLL‐patients may indicate that AAV‐2 antibody‐positive HTLV‐I carriers might be less likely to develop ATLL or that loss of AAV‐2 antibodies may parallel the development of disease. J. Med. Virol. 65:185–189, 2001. © 2001 Wiley‐Liss, Inc.</description><subject>AAV</subject><subject>Adeno-associated virus 2</subject><subject>Adeno-associated virus type 2</subject><subject>Antibodies, Viral - blood</subject><subject>ATLL</subject><subject>Biological and medical sciences</subject><subject>Carrier State</subject><subject>Dependovirus - immunology</subject><subject>EBNA1 antigen</subject><subject>ELISA</subject><subject>Epstein-Barr virus</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>HTLV-I</subject><subject>HTLV‐I, ELISA</subject><subject>Human T-lymphotropic virus 1</subject><subject>Human T-lymphotropic virus 1 - immunology</subject><subject>Humans</subject><subject>Immunoglobulin G - blood</subject><subject>Leukemia-Lymphoma, Adult T-Cell - immunology</subject><subject>Leukemia-Lymphoma, Adult T-Cell - virology</subject><subject>Male</subject><subject>Microbiology</subject><subject>Parvoviridae Infections - epidemiology</subject><subject>Parvoviridae Infections - immunology</subject><subject>Parvoviridae Infections - virology</subject><subject>Prevalence</subject><subject>Seroepidemiologic Studies</subject><subject>seroepidemiology</subject><subject>tumour suppression</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U1v1DAQBmALgei2IPELkC9UvaT1OIkTH1FFW1BbECofN2viTKjbfGE7W_bAfyerjegJcfLl8TujeRl7BeIYhJAnd936WArQT9gKhFaJFgU8ZSsBmUqUgnyP7YdwJ4QotZTP2R5ALvJMyRX7_ZnqyVLNR09rbKm3xIeGB_JTx7GPrhpqR4HjD3R9iBxr6ocEQxiswzj_Wzs_BR43I3HJXc9HjI76GPiDi7czn9rIbxJLbctbmu6ROoe83XTj7dDhC_aswTbQy-U9YF_O3t2cXiSXH8_fn769TGwGSiclWlkBQJFltlGqklYpLctSUy4qhbKoSOdEdZZqbGpbCiBoUqiaPC0zWVJ6wA53uaMffk4Uoulc2O6EPQ1TMMV8NZBa_hdCocU8OJ_h0Q5aP4TgqTGjdx36jQFhtp2YuROz7WSmr5fMqeqofoRLCTN4swAMFtvGY29deHTzDbJSbIOSnXtwLW3-OdB8uPq6DF68C5F-_fXo740q0iI3367PjSqlzD9dnZnv6R8V8bKf</recordid><startdate>200109</startdate><enddate>200109</enddate><creator>Walz, Christian M.</creator><creator>Nakamura, Minoru</creator><creator>Fukunaga, Toshihiko</creator><creator>Jasiewicz, Yvonne</creator><creator>Edler, Lutz</creator><creator>Schlehofer, Jörg R.</creator><creator>Tanaka, Yuetsu</creator><general>John Wiley & Sons, Inc</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200109</creationdate><title>Reduced prevalence of serum antibodies against adeno-associated virus type 2 in patients with adult T-cell leukaemia lymphoma</title><author>Walz, Christian M. ; Nakamura, Minoru ; Fukunaga, Toshihiko ; Jasiewicz, Yvonne ; Edler, Lutz ; Schlehofer, Jörg R. ; Tanaka, Yuetsu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4169-8ac2b111744cf66b2c6692889e50b6a27be95eed439afdc801e1f31bf538428e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>AAV</topic><topic>Adeno-associated virus 2</topic><topic>Adeno-associated virus type 2</topic><topic>Antibodies, Viral - blood</topic><topic>ATLL</topic><topic>Biological and medical sciences</topic><topic>Carrier State</topic><topic>Dependovirus - immunology</topic><topic>EBNA1 antigen</topic><topic>ELISA</topic><topic>Epstein-Barr virus</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>HTLV-I</topic><topic>HTLV‐I, ELISA</topic><topic>Human T-lymphotropic virus 1</topic><topic>Human T-lymphotropic virus 1 - immunology</topic><topic>Humans</topic><topic>Immunoglobulin G - blood</topic><topic>Leukemia-Lymphoma, Adult T-Cell - immunology</topic><topic>Leukemia-Lymphoma, Adult T-Cell - virology</topic><topic>Male</topic><topic>Microbiology</topic><topic>Parvoviridae Infections - epidemiology</topic><topic>Parvoviridae Infections - immunology</topic><topic>Parvoviridae Infections - virology</topic><topic>Prevalence</topic><topic>Seroepidemiologic Studies</topic><topic>seroepidemiology</topic><topic>tumour suppression</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walz, Christian M.</creatorcontrib><creatorcontrib>Nakamura, Minoru</creatorcontrib><creatorcontrib>Fukunaga, Toshihiko</creatorcontrib><creatorcontrib>Jasiewicz, Yvonne</creatorcontrib><creatorcontrib>Edler, Lutz</creatorcontrib><creatorcontrib>Schlehofer, Jörg R.</creatorcontrib><creatorcontrib>Tanaka, Yuetsu</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walz, Christian M.</au><au>Nakamura, Minoru</au><au>Fukunaga, Toshihiko</au><au>Jasiewicz, Yvonne</au><au>Edler, Lutz</au><au>Schlehofer, Jörg R.</au><au>Tanaka, Yuetsu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced prevalence of serum antibodies against adeno-associated virus type 2 in patients with adult T-cell leukaemia lymphoma</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J. Med. Virol</addtitle><date>2001-09</date><risdate>2001</risdate><volume>65</volume><issue>1</issue><spage>185</spage><epage>189</epage><pages>185-189</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><coden>JMVIDB</coden><abstract>Seroepidemiological studies have shown previously that cancer patients are less likely to have antibodies against the tumour suppressive adeno‐associated virus (AAV) than control groups. To examine the influence of AAV infection on the development of adult T‐cell leukaemia lymphoma (ATLL), an endemic disease in Southern Japan that is caused by infection with the human T‐cell leukaemia virus type 1 (HTLV‐I), the prevalence of serum antibodies to AAV type 2 (AAV‐2) was tested in healthy HTLV‐I carriers (n = 39) and patients with ATLL (n = 31). The results showed a significant difference in AAV‐2 seropositivity between the two groups: Only 29% of the ATLL patients had IgG antibodies against AAV‐2, whereas 84.6% of the healthy HTLV‐I carriers were seropositive. Analysis of total serum IgG and antibodies against the Epstein‐Barr virus (EBV) EBNA1 antigen showed that the lack of AAV antibodies in patients was not due to an ATLL‐associated immune deficiency. The lower level of AAV‐2 seropositivity in ATLL‐patients may indicate that AAV‐2 antibody‐positive HTLV‐I carriers might be less likely to develop ATLL or that loss of AAV‐2 antibodies may parallel the development of disease. J. Med. Virol. 65:185–189, 2001. © 2001 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>11505462</pmid><doi>10.1002/jmv.2019</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2001-09, Vol.65 (1), p.185-189 |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71091292 |
| source | MEDLINE; Wiley Journals |
| subjects | AAV Adeno-associated virus 2 Adeno-associated virus type 2 Antibodies, Viral - blood ATLL Biological and medical sciences Carrier State Dependovirus - immunology EBNA1 antigen ELISA Epstein-Barr virus Female Fundamental and applied biological sciences. Psychology HTLV-I HTLV‐I, ELISA Human T-lymphotropic virus 1 Human T-lymphotropic virus 1 - immunology Humans Immunoglobulin G - blood Leukemia-Lymphoma, Adult T-Cell - immunology Leukemia-Lymphoma, Adult T-Cell - virology Male Microbiology Parvoviridae Infections - epidemiology Parvoviridae Infections - immunology Parvoviridae Infections - virology Prevalence Seroepidemiologic Studies seroepidemiology tumour suppression |
| title | Reduced prevalence of serum antibodies against adeno-associated virus type 2 in patients with adult T-cell leukaemia lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A26%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20prevalence%20of%20serum%20antibodies%20against%20adeno-associated%20virus%20type%202%20in%20patients%20with%20adult%20T-cell%20leukaemia%20lymphoma&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Walz,%20Christian%20M.&rft.date=2001-09&rft.volume=65&rft.issue=1&rft.spage=185&rft.epage=189&rft.pages=185-189&rft.issn=0146-6615&rft.eissn=1096-9071&rft.coden=JMVIDB&rft_id=info:doi/10.1002/jmv.2019&rft_dat=%3Cproquest_cross%3E17902885%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17902885&rft_id=info:pmid/11505462&rfr_iscdi=true |